Compounded Semaglutide
Compounded semaglutide is a GLP-1 receptor agonist prepared by a state-licensed compounding pharmacy. GLP-1 receptor agonists work by mimicking the GLP-1 hormone — signaling the brain to reduce appetite, slowing gastric emptying, and supporting blood sugar regulation.
Compounded semaglutide is not FDA-approved and is not the same as commercially manufactured brand-name drugs. Safety and efficacy have not been established for this compounded formulation. FDA-approved GLP-1 products have established safety and efficacy; compounded versions do not carry the same regulatory assurances.
Once-Weekly Injection
Subcutaneous self-injection in the abdomen, thigh, or upper arm.
Gradual Titration
Starts at 0.25mg/week, increases over 16+ weeks to 2.4mg maintenance.
Ships Monthly
Multi-dose vial with syringes and supplies included every month.
Provider Check-Ins
Monthly clinical review, dose adjustments, and ongoing support.
Standard Titration Schedule
| Weeks | Dose | Phase | Monthly Price |
|---|---|---|---|
| 1–4 | 0.25 mg/week | Initiation | $249/mo |
| 5–8 | 0.5 mg/week | Titration | $249/mo |
| 9–12 | 1.0 mg/week | Titration | $299/mo |
| 13–16 | 1.7 mg/week | Titration | $329/mo |
| 17+ | 2.4 mg/week | Maintenance | $349/mo |
Your prescriber may adjust this schedule based on tolerability and response. Dose increases are not automatic — they require provider approval at each monthly check-in.
Important: Compounded vs. FDA-Approved
Compounded semaglutide is not FDA-approved. FDA approval means a drug has been reviewed by the agency for safety and efficacy in the specific form being sold. Compounded medications do not go through that review process. Do not assume that compounded semaglutide will produce the same outcomes as FDA-approved products. Discuss all options — including FDA-approved alternatives — with your prescribing provider.
